

Sudan, Republic of

Support for Vaccine: Pentavalent This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Sudan, Republic of						
2. Vaccine grant number:	0810-SDN-04a-X, 1114-SDN-04A-X, 1516-SDN-04a-X, 17-SDN-04a-X, 1820-SDN-04a-X						
3. Date of Decision Letter:	11-Jul-19						
4. Date of the Partnership Framework Agreement:	December 10, 2013						
5. Programme title:	New Vaccine Support (NVS), Pentavalent, Routine						
6. Vaccine type:	Pentavalent						
7. Requested product presentation and formulation of vaccine:	DTP-HepB-Hib, 1 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2007-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2007-2018	2019	2020	2021	2022	2023	Total ²
Programme Budget (US\$)	98,033,355	4,442,500	4,762,500	-	-	-	107,238,355
10. Vaccine introduction grant	Not applicable						
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2007-2018	2019					2020
Number of vaccine doses					3,964,300		-
Annual Amounts (US\$)	98,033,355	4,442,500					-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement:	Not applicable						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the total amount approved by Gavi.

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	654,900	827,900	-	-	-
Number of AD syringes	698,000	884,400	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	7,700	9,750	-	-	-
Value of vaccine doses (US\$)	687,554	869,265	-	-	-
Total co-financing payments (US\$) (including freight)	765,500	968,000	-	-	-

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>March 31, 2020</p> <p>May 15, 2020</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	Periodicity and dates to be agreed with Gavi Secretariat

18. Financial clarifications:

Country shall provide the following clarifications to Gavi*:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:

Not applicable

On behalf of Gavi



Pascal Bijleveld
Managing Director, Country Programmes a.i.